Amgen Reports Positive Data From AMG 510 Early Phase 1 Study - Quick Facts

(RTTNews) - Amgen (AMGN) said a Phase 1 study evaluating investigational AMG 510 showed anti-tumor activity when administered as a monotherapy in patients with locally-advanced or metastatic KRASG12C mutant solid tumors. There were no dose-limiting toxicities at tested dose levels. Regarding safety data from the phase 1 study, Amgen said treatment-related adverse events were primarily grade 1 events. Enrollment into dose expansion is underway.

AMG 510 is the first KRASG12C inhibitor to reach clinical stage. The first-in-human study enrolled 35 patients with various tumor types.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AMGN